PL412787A1 - Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną - Google Patents

Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną

Info

Publication number
PL412787A1
PL412787A1 PL412787A PL41278715A PL412787A1 PL 412787 A1 PL412787 A1 PL 412787A1 PL 412787 A PL412787 A PL 412787A PL 41278715 A PL41278715 A PL 41278715A PL 412787 A1 PL412787 A1 PL 412787A1
Authority
PL
Poland
Prior art keywords
ferritin
active
delivery system
contrast
targeted delivery
Prior art date
Application number
PL412787A
Other languages
English (en)
Inventor
Magdalena Król
Irene Benni
Paola Baiocco
Original Assignee
Magdalena Król
Istituto Italiano Di Tecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magdalena Król, Istituto Italiano Di Tecnologia filed Critical Magdalena Król
Priority to PL412787A priority Critical patent/PL412787A1/pl
Priority to MYPI2017001887A priority patent/MY195009A/en
Priority to HK18113067.1A priority patent/HK1253919B/en
Priority to EP16733390.5A priority patent/EP3310905B1/en
Priority to HRP20240685TT priority patent/HRP20240685T1/hr
Priority to FIEP16732271.8T priority patent/FI3310904T3/fi
Priority to CA2989489A priority patent/CA2989489A1/en
Priority to EP24167623.8A priority patent/EP4406544A3/en
Priority to ES16733390T priority patent/ES2984620T3/es
Priority to US15/739,382 priority patent/US11464879B2/en
Priority to PCT/EP2016/064483 priority patent/WO2016207256A1/en
Priority to US15/739,392 priority patent/US20200030468A1/en
Priority to CN201680047506.5A priority patent/CN108026514A/zh
Priority to JP2017567293A priority patent/JP7092505B2/ja
Priority to LTEPPCT/EP2016/064484T priority patent/LT3310904T/lt
Priority to EP16732271.8A priority patent/EP3310904B1/en
Priority to KR1020227003859A priority patent/KR102447396B1/ko
Priority to ES16732271T priority patent/ES2979087T3/es
Priority to SI201631827T priority patent/SI3310904T1/sl
Priority to CA2989491A priority patent/CA2989491C/en
Priority to JP2017567303A priority patent/JP7053269B2/ja
Priority to NZ739133A priority patent/NZ739133A/en
Priority to DK16732271.8T priority patent/DK3310904T3/da
Priority to HUE16732271A priority patent/HUE067635T2/hu
Priority to PCT/EP2016/064484 priority patent/WO2016207257A1/en
Priority to AU2016282846A priority patent/AU2016282846B2/en
Priority to CN201680047507.XA priority patent/CN108138143A/zh
Priority to EA201890079A priority patent/EA039755B1/ru
Priority to BR112017027876-6A priority patent/BR112017027876B1/pt
Priority to KR1020217016460A priority patent/KR20210075196A/ko
Priority to PL16733390.5T priority patent/PL3310905T3/pl
Priority to MX2017017079A priority patent/MX2017017079A/es
Priority to KR1020187001583A priority patent/KR20180027521A/ko
Priority to PT167322718T priority patent/PT3310904T/pt
Priority to PL16732271.8T priority patent/PL3310904T3/pl
Priority to IL256363A priority patent/IL256363B/en
Priority to KR1020227032814A priority patent/KR102621732B1/ko
Priority to RU2018144424A priority patent/RU2771323C2/ru
Priority to CA3027531A priority patent/CA3027531A1/en
Priority to US16/312,726 priority patent/US20190328911A1/en
Priority to JP2019519948A priority patent/JP7045370B2/ja
Priority to KR1020197001831A priority patent/KR102796258B1/ko
Priority to AU2016410262A priority patent/AU2016410262B2/en
Publication of PL412787A1 publication Critical patent/PL412787A1/pl
Priority to CL2017003307A priority patent/CL2017003307A1/es
Priority to US17/361,897 priority patent/US12485192B2/en
Priority to US17/745,016 priority patent/US20220280663A1/en
Priority to US17/931,576 priority patent/US20240060045A1/en
Priority to US18/951,987 priority patent/US20250075182A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Wynalazek dotyczy celowanego systemu dostarczania obejmującego aktywowane mikrofagi zawierające ferrytynę przenoszącą substancję czynną lub kontrastującą, a także sposobu wytwarzania celowanego systemu dostarczania obejmującego aktywowane mikrofagi zawierające ferrytynę przenoszącą substancję czynną lub kontrastującą. Sposób wytwarzania odbywa się etapami: a) oczyszczenie ferrytyny b) uzyskanie ferrytyny przenoszącej substancję czynną lub kontrastującą poprzez połączenie ferrytyny z wymienioną substancją czynną lub kontrastującą; c) aktywację wyizolowanych makrofagów; d) inkubację makrofagów w roztworze zawierającej substancję czynną lub substancją kontrastującą uzyskaną w etapie b) w czasie i stężeniu ferrytyny odpowiednim do uzyskania pełnego wysycenia makrofagów ferrytyną zawierającą substancję czynną lub kontrastującą. Ujawniono również zastosowania celowanego systemu dostarczania w leczeniu lub obrazowaniu chorób zapalnych i miejsc niedotlenionych.
PL412787A 2015-06-22 2015-06-22 Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną PL412787A1 (pl)

Priority Applications (48)

Application Number Priority Date Filing Date Title
PL412787A PL412787A1 (pl) 2015-06-22 2015-06-22 Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
MYPI2017001887A MY195009A (en) 2015-06-22 2016-06-22 Cellular Targeted Active Ingredient Delivery System
HK18113067.1A HK1253919B (en) 2015-06-22 2016-06-22 Cellular targeted active ingredient delivery system
EP16733390.5A EP3310905B1 (en) 2015-06-22 2016-06-22 Cellular targeted label delivery system
HRP20240685TT HRP20240685T1 (hr) 2015-06-22 2016-06-22 Sustav isporuke stanično ciljanog aktivnog sastojka
FIEP16732271.8T FI3310904T3 (fi) 2015-06-22 2016-06-22 Solukkokohdisteinen aktiivisten ainesosien toimitusjärjestelmä
CA2989489A CA2989489A1 (en) 2015-06-22 2016-06-22 Cellular targeted label delivery system
EP24167623.8A EP4406544A3 (en) 2015-06-22 2016-06-22 Cellular targeted active ingredient delivery system
ES16733390T ES2984620T3 (es) 2015-06-22 2016-06-22 Sistema de suministro de marcadores objetivo celulares
US15/739,382 US11464879B2 (en) 2015-06-22 2016-06-22 Cellular targeted active ingredient delivery system
PCT/EP2016/064483 WO2016207256A1 (en) 2015-06-22 2016-06-22 Cellular targeted label delivery system
US15/739,392 US20200030468A1 (en) 2015-06-22 2016-06-22 Cellular Targeted Label Delivery System
CN201680047506.5A CN108026514A (zh) 2015-06-22 2016-06-22 细胞靶向标记物递送体系
JP2017567293A JP7092505B2 (ja) 2015-06-22 2016-06-22 細胞標的化有効成分送達系
LTEPPCT/EP2016/064484T LT3310904T (lt) 2015-06-22 2016-06-22 Ląstelinė kryptinga sistema aktyvių ingredientų tiekimui
EP16732271.8A EP3310904B1 (en) 2015-06-22 2016-06-22 Cellular targeted active ingredient delivery system
KR1020227003859A KR102447396B1 (ko) 2015-06-22 2016-06-22 세포 표적화된 활성 성분 전달 시스템
ES16732271T ES2979087T3 (es) 2015-06-22 2016-06-22 Sistema de administración de principio activo dirigido a las células
SI201631827T SI3310904T1 (sl) 2015-06-22 2016-06-22 Celični tarčni dostavni sistem za dostavo učinkovin
CA2989491A CA2989491C (en) 2015-06-22 2016-06-22 Cellular targeted active ingredient delivery system
JP2017567303A JP7053269B2 (ja) 2015-06-22 2016-06-22 細胞標的化標識送達系
NZ739133A NZ739133A (en) 2015-06-22 2016-06-22 Cellular targeted active ingredient delivery system
DK16732271.8T DK3310904T3 (da) 2015-06-22 2016-06-22 System til cellulær indgivelse af målrettet aktivstof
HUE16732271A HUE067635T2 (hu) 2015-06-22 2016-06-22 Sejtszintû célzott hatóanyag-szállító rendszer
PCT/EP2016/064484 WO2016207257A1 (en) 2015-06-22 2016-06-22 Cellular targeted active ingredient delivery system
AU2016282846A AU2016282846B2 (en) 2015-06-22 2016-06-22 Cellular targeted active ingredient delivery system
CN201680047507.XA CN108138143A (zh) 2015-06-22 2016-06-22 细胞靶向的活性成分递送体系
EA201890079A EA039755B1 (ru) 2015-06-22 2016-06-22 Клеточная система для направленной доставки активного ингредиента
BR112017027876-6A BR112017027876B1 (pt) 2015-06-22 2016-06-22 Sistema de distribuição, método de preparação do sistema e composição farmacêutica
KR1020217016460A KR20210075196A (ko) 2015-06-22 2016-06-22 세포 표적화된 활성 성분 전달 시스템
PL16733390.5T PL3310905T3 (pl) 2015-06-22 2016-06-22 Komórkowy układ ukierunkowanego dostarczania etykiety
MX2017017079A MX2017017079A (es) 2015-06-22 2016-06-22 Sistema de administracion dirigida de principio activo celular.
KR1020187001583A KR20180027521A (ko) 2015-06-22 2016-06-22 세포 표적화된 활성 성분 전달 시스템
PT167322718T PT3310904T (pt) 2015-06-22 2016-06-22 Sistema celular de administração dirigida de ingrediente ativo
PL16732271.8T PL3310904T3 (pl) 2015-06-22 2016-06-22 Komórkowy układ ukierunkowanego dostarczania substancji czynnej
IL256363A IL256363B (en) 2015-06-22 2016-06-22 A cell-targeted active ingredient delivery system
KR1020227032814A KR102621732B1 (ko) 2015-06-22 2016-06-22 세포 표적화된 활성 성분 전달 시스템
RU2018144424A RU2771323C2 (ru) 2015-06-22 2016-12-21 Клеточная система направленной доставки фармацевтически активного вещества или метки
CA3027531A CA3027531A1 (en) 2015-06-22 2016-12-21 Cellular targeted pharmaceutically active substance or label delivery system
US16/312,726 US20190328911A1 (en) 2015-06-22 2016-12-21 Cellular targeted pharmaceutically active substance or label delivery system
JP2019519948A JP7045370B2 (ja) 2015-06-22 2016-12-21 細胞標的化された薬学的に活性な物質または標識送達系
KR1020197001831A KR102796258B1 (ko) 2015-06-22 2016-12-21 세포 표적화된 약학적으로 활성인 물질 또는 표지 전달 시스템
AU2016410262A AU2016410262B2 (en) 2015-06-22 2016-12-21 Cellular targeted pharmaceutically active substance or label delivery system
CL2017003307A CL2017003307A1 (es) 2015-06-22 2017-12-21 Sistema de administración dirigida de principio activo celular
US17/361,897 US12485192B2 (en) 2015-06-22 2021-06-29 Cellular targeted label delivery system
US17/745,016 US20220280663A1 (en) 2015-06-22 2022-05-16 Cellular targeted pharmaceutically active substance or label delivery system
US17/931,576 US20240060045A1 (en) 2015-06-22 2022-09-13 Cellular targeted active ingredient delivery system
US18/951,987 US20250075182A1 (en) 2015-06-22 2024-11-19 Cellular targeted active ingredient delivery system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL412787A PL412787A1 (pl) 2015-06-22 2015-06-22 Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną

Publications (1)

Publication Number Publication Date
PL412787A1 true PL412787A1 (pl) 2017-01-02

Family

ID=56235808

Family Applications (3)

Application Number Title Priority Date Filing Date
PL412787A PL412787A1 (pl) 2015-06-22 2015-06-22 Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
PL16733390.5T PL3310905T3 (pl) 2015-06-22 2016-06-22 Komórkowy układ ukierunkowanego dostarczania etykiety
PL16732271.8T PL3310904T3 (pl) 2015-06-22 2016-06-22 Komórkowy układ ukierunkowanego dostarczania substancji czynnej

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL16733390.5T PL3310905T3 (pl) 2015-06-22 2016-06-22 Komórkowy układ ukierunkowanego dostarczania etykiety
PL16732271.8T PL3310904T3 (pl) 2015-06-22 2016-06-22 Komórkowy układ ukierunkowanego dostarczania substancji czynnej

Country Status (24)

Country Link
US (5) US20200030468A1 (pl)
EP (3) EP4406544A3 (pl)
JP (3) JP7053269B2 (pl)
KR (5) KR20210075196A (pl)
CN (2) CN108026514A (pl)
AU (2) AU2016282846B2 (pl)
CA (2) CA2989489A1 (pl)
CL (1) CL2017003307A1 (pl)
DK (1) DK3310904T3 (pl)
EA (1) EA039755B1 (pl)
ES (2) ES2979087T3 (pl)
FI (1) FI3310904T3 (pl)
HR (1) HRP20240685T1 (pl)
HU (1) HUE067635T2 (pl)
IL (1) IL256363B (pl)
LT (1) LT3310904T (pl)
MX (1) MX2017017079A (pl)
MY (1) MY195009A (pl)
NZ (1) NZ739133A (pl)
PL (3) PL412787A1 (pl)
PT (1) PT3310904T (pl)
RU (1) RU2771323C2 (pl)
SI (1) SI3310904T1 (pl)
WO (2) WO2016207256A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
WO2017222398A1 (en) * 2016-06-22 2017-12-28 Cellis Sp. Z O.O. Cellular targeted pharmaceutically active substance or label delivery system
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
CN108671237A (zh) * 2018-05-31 2018-10-19 同济大学 一种增强药物靶向递送的载体及其获得方法与应用
WO2020018434A1 (en) * 2018-07-17 2020-01-23 Scripps Health Compositions and methods for disrupting a macrophage network
US20210381006A1 (en) * 2018-10-18 2021-12-09 Takeda Pharmaceutical Company Limited Method for activation/proliferation of t cells
EP3650046A1 (en) 2018-11-08 2020-05-13 Cellis AG Mesenchymal stem cell based targeted active ingredient delivery system
WO2020236952A1 (en) * 2019-05-20 2020-11-26 Ohio State Innovation Foundation Apohemoglobin-haptoglobin complexes and methods of using thereof
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
US12410401B2 (en) * 2019-06-06 2025-09-09 Wisconsin Alumni Research Foundation (Warf) Generation of functional neutrophils and macrophages from induced pluripotent stem cells in chemically defined conditions using transient expression of ETV2
WO2021137611A1 (ko) * 2019-12-30 2021-07-08 (주)테라베스트 나노 구조체가 부착된 면역세포
JP2023518932A (ja) * 2020-03-18 2023-05-09 セリス アーゲー 安定性、複合体形成能力及びトランスフェリン受容体親和性が向上したフェリチン変異体
JPWO2021251358A1 (pl) * 2020-06-09 2021-12-16
CN115671258A (zh) * 2021-01-22 2023-02-03 复旦大学附属华山医院 用于促进m2型巨噬细胞极化的细胞因子组合物及其应用
CN113367335B (zh) * 2021-06-24 2022-05-06 中国农业大学 一种提高虾青素水溶性且保护其免受Fe2+氧化降解的方法
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
JP2025532550A (ja) 2022-09-13 2025-10-01 セリス アーゲー 神経膠腫の処置用の単離標的化送達系
EP4637829A1 (en) 2022-12-20 2025-10-29 Cellis Sp. z o.o. ([Ltd.] Isolated targeted delivery system for the treatment of ovarian cancer
KR20240137420A (ko) * 2023-03-08 2024-09-20 주식회사 메디아크 금속-유기 골격체를 포함하는 대식세포 분극화 유도용 조성물 및 이의 용도
WO2025083276A1 (en) 2023-10-19 2025-04-24 Cellis Ag Improved isolated targeted delivery system

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
CA2122717C (en) 1991-11-08 2003-07-15 David C. Anderson Hemoglobins as drug delivery agents
US6680052B1 (en) * 1999-11-08 2004-01-20 Endacea, Inc. Methods of inhibiting tumor growth using adenosine receptor activated cells
WO2003094849A2 (en) * 2002-05-10 2003-11-20 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
ES2389532T3 (es) 2005-06-29 2012-10-29 Threshold Pharmaceuticals, Inc. Profármacos alquilantes de fosforamidato
US20090123366A1 (en) 2006-04-03 2009-05-14 Keele University Targeted Therapy
GB0606660D0 (en) * 2006-04-03 2006-05-10 Univ Keele Targeted Therapy
CA2649294A1 (en) 2006-04-14 2008-05-08 Celsense, Inc. Methods for assessing cell labeling
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US8951561B2 (en) * 2007-08-06 2015-02-10 Duke University Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP)
JP2013523651A (ja) 2010-03-24 2013-06-17 ノースイースタン ユニヴァーシティ 多重コンパートメントのマクロファージ送達
US20120087860A1 (en) * 2010-05-24 2012-04-12 Marek Malecki Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags
WO2012012786A2 (en) * 2010-07-22 2012-01-26 Brigham Young University Process, composition and method for anion deposition into ferritin for therapeutic and other use
CN103124784A (zh) * 2010-08-23 2013-05-29 纽约州立大学研究基金会 用于扩增干细胞的方法和这些细胞的用途
US9314304B2 (en) * 2010-12-08 2016-04-19 Lumicell, Inc. Methods and system for image guided cell ablation with microscopic resolution
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
CA2921493A1 (en) * 2012-08-21 2014-02-27 Brown University Ferritin-based tumor targeting agent, and imaging and treatment methods
MX2015006096A (es) * 2012-11-19 2015-12-01 Deryl L Troyer Leucocitos como celulas de administracion para imagen y terapia de enfermedad.
JP6425308B2 (ja) 2013-06-28 2018-11-21 株式会社ＡｄｉｐｏＳｅｅｄｓ 間葉系細胞を利用した巨核球、血小板及び／又はトロンボポエチンの製造方法
WO2015012315A1 (ja) 2013-07-24 2015-01-29 愛知県 末梢循環腫瘍細胞又は希少細胞分離用デバイス、及び末梢循環腫瘍細胞又は希少細胞分離方法
RU2552609C1 (ru) 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
WO2015135597A1 (en) * 2014-03-12 2015-09-17 Cic Nanogune - Asociación Centro De Investigación Cooperativa En Nanociencias Uses and methods for delivery to the nucleus
PL412787A1 (pl) 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną

Also Published As

Publication number Publication date
EP3310905B1 (en) 2024-04-17
KR102621732B1 (ko) 2024-01-05
KR20180027521A (ko) 2018-03-14
JP7045370B2 (ja) 2022-03-31
KR102796258B1 (ko) 2025-04-18
US20220280663A1 (en) 2022-09-08
KR20210075196A (ko) 2021-06-22
US20200030468A1 (en) 2020-01-30
HRP20240685T1 (hr) 2024-09-27
IL256363A (en) 2018-02-28
MY195009A (en) 2022-12-30
PL3310904T3 (pl) 2024-07-15
CA2989489A1 (en) 2016-12-29
EP3310905A1 (en) 2018-04-25
WO2016207257A1 (en) 2016-12-29
JP2018520673A (ja) 2018-08-02
PL3310905T3 (pl) 2024-07-15
EP3310904A1 (en) 2018-04-25
EA201890079A1 (ru) 2018-07-31
ES2979087T3 (es) 2024-09-24
PT3310904T (pt) 2024-06-18
AU2016410262B2 (en) 2023-06-15
EP4406544A3 (en) 2025-01-01
RU2018144424A (ru) 2020-07-22
SI3310904T1 (sl) 2024-10-30
US20200030374A1 (en) 2020-01-30
NZ739133A (en) 2021-12-24
EP3310904B1 (en) 2024-04-03
CN108026514A (zh) 2018-05-11
CN108138143A (zh) 2018-06-08
JP2018518525A (ja) 2018-07-12
AU2016282846B2 (en) 2021-02-18
JP7053269B2 (ja) 2022-04-12
MX2017017079A (es) 2018-05-15
KR20220132676A (ko) 2022-09-30
CA2989491A1 (en) 2016-12-29
AU2016410262A1 (en) 2019-01-24
KR20220025105A (ko) 2022-03-03
US12485192B2 (en) 2025-12-02
AU2016282846A1 (en) 2018-02-15
EP4406544A2 (en) 2024-07-31
IL256363B (en) 2022-09-01
JP2019518479A (ja) 2019-07-04
KR102447396B1 (ko) 2022-09-27
LT3310904T (lt) 2024-07-10
ES2984620T3 (es) 2024-10-30
US20210322584A1 (en) 2021-10-21
US20190328911A1 (en) 2019-10-31
EA039755B1 (ru) 2022-03-10
HUE067635T2 (hu) 2024-12-28
WO2016207256A1 (en) 2016-12-29
JP7092505B2 (ja) 2022-06-28
KR20190038540A (ko) 2019-04-08
DK3310904T3 (da) 2024-06-10
RU2018144424A3 (pl) 2020-07-22
BR112017027876A2 (pt) 2018-09-11
CL2017003307A1 (es) 2018-04-13
EP3310905C0 (en) 2024-04-17
CA3027531A1 (en) 2017-12-28
FI3310904T3 (fi) 2024-05-28
RU2771323C2 (ru) 2022-04-29
HK1253919A1 (en) 2019-07-05
US11464879B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
PL412787A1 (pl) Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20160841A1 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
CL2015003355A1 (es) Derivados del bipirazol como inhibidores jak
MX380239B (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona.
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
PL399505A1 (pl) Sposób wytwarzania zasadniczo czystych nanoczastek w ukladzie przeplywowym, nanoczastki otrzymane tym sposobem oraz ich zastosowanie
SG10201811186XA (en) Purification of proteins
MX2020010375A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
MX2020005079A (es) Derivados de aminotiazol utiles como agentes antiviricos.
PH12016502003A1 (en) Novel bacteriophage and composition containing same
EP3336095A4 (en) OXIDIZED BETA-1,4-OLIGOGLUCURONIC ACID AND METHOD OF MANUFACTURING THEREOF AND USES THEREOF
EP3299395A4 (en) OXIDIZED 1,4-OLIGOGLUCURONIC ACID, MANUFACTURING METHOD AND USES THEREOF
EP4541380A3 (en) Stable, concentrated radionuclide complex solutions
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
TW201613953A (en) Process for the preparation of cyclic depsipeptides
PH12017501872A1 (en) Methods of treating diseases
MY172146A (en) Insecticidal water-in-oil (w/o) formulation
MY172656A (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
CR20150594A (es) N-(2-fluoro-2-fenetil)carboxamidas como nematicidas y endoparasiticidas
IN2013MU00916A (pl)
HK1202868A1 (en) Carboxamide-substituted heteroaryl-pyrazoles and the use thereof
PH12017502253B1 (en) Imidazodiazepine compound
CY1118614T1 (el) Νεα παραγωγα (αζα)βενζυδρυλαιθερα, διεργασια παρασκευης τους και χρηση τους ως προσδετες h4-υποδοχεα για θεραπευτικες εφαρμογες